| Companies sponsors |
Pierre Fabre (vibegron) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Bladder and Bowel Community |
| |
Bladder and Bowel UK |
| |
Bladder Health UK |
| |
Cystitis and Overactive Bladder Foundation |
| |
Kidney Care UK |
| |
Kidney Patient Involvement Network |
| |
Kidney Research UK |
| |
National Kidney Federation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| Professional groups |
Association for Continence Advice |
| |
Association of British Neurologists |
| |
Association of Renal Technologists Physicians |
| |
British Association of Urological Nurses |
| |
British Association of Urological Surgeons |
| |
British Geriatrics Society |
| |
British Society of Urogynaecology |
| |
National Neuroscience Advisory Group |
| |
Royal College of Emergency Medicine |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Obstetricians and Gynaecologists |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society for DGH Nephrologists |
| |
Society for Vascular Nurses |
| |
The Urology Foundation |
| |
UK Clinical Pharmacy Association |
| |
UK Renal Pharmacy Group |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Aristo Pharma (fesoterodine) |
| |
Aspire Pharma (darifenacin, fesoterodine, solifenacin, tolterodine) |
| |
Astellas Pharma (mirabegron, solifenacin) |
| |
Aurobindo Pharma – Milpharm (solifenacin) |
| |
Brillpharma (oxybutynin) |
| |
Brown & Burk (solifenacin) |
| |
Celix Pharma (fesoterodine, solifenacin) |
| |
Dr. Reddy's Laboratories (fesoterodine) |
| |
Genus Pharmaceuticals (fesoterodine, solifenacin) |
| |
Ennogen Healthcare (propiverine) |
| |
Glenmark Pharmaceuticals (solifenacin, trospium) |
| |
Krka (solifenacin) |
| |
Medical Valley Invest (fesoterodine) |
| |
MSN Laboratories (solifenacin) |
| |
Neon Healthcare (oxybutynin) |
| |
Northumbria Pharma (tolterodine) |
| |
Pfizer (fesoterodine) |
| |
Ranbaxy, a Sun Pharmaceutical Company (solifenacin) |
| |
Roma Pharmaceuticals (oxybutynin) |
| |
Sandoz (solifenacin, tolterodine) |
| |
Strides Pharma (oxybutynin) |
| |
Tillomed Laboratories (oxybutynin, solifenacin) |
| |
Viatris (tolterodine, trospium) |
| |
Zentiva (fesoterodine, oxybutynin, solifenacin, tolterodine) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group |
| |
Cochrane UK |
| |
Cochrane Urology |
| |
Genomics England |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |
| |
The Society for Research in Rehabilitation |
| |
Wellcome Trust |